Sign inCreate account

Report workspace

Add to folder
NCT00445172COMPLETEDanonymous

A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Sponsor

Source record

Eisai Co., Ltd.

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

E0302 (mecobalamin)

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis (ALS)

Intervention

Source record

E0302 (mecobalamin)

Related intelligence directories

Indication directory: Amyotrophic Lateral Sclerosis (ALS)Modality directory: small moleculeTarget directory: E0302 (mecobalamin)

Source & freshness

Source record

NCT ID

NCT00445172

Original source

ClinicalTrials.gov

Source last updated

Jun 18, 2023

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00445172

Title

A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Sponsor

Eisai Co., Ltd.

Status

COMPLETED

Phase

PHASE2

Condition raw

Amyotrophic Lateral Sclerosis (ALS)

Condition normalized

Amyotrophic Lateral Sclerosis (ALS)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

E0302 (mecobalamin)

Target normalized

E0302 (mecobalamin)

Interventions

E0302 (mecobalamin)

Public preview

Source record

The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT00445172

Status

COMPLETED

Phase

PHASE2

Sponsor

Eisai Co., Ltd.

Executive brief

Investment-Ready Snapshot

The purpose of this study is to investigate the safety and efficacy of long-term E0302 administration in patients with Amyotrophic Lateral Sclerosis (ALS).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 18, 2023
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00445172

Indication

Amyotrophic Lateral Sclerosis (ALS)

Modality

small molecule

Target

E0302 (mecobalamin)

Intervention

E0302 (mecobalamin)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.